Merck Launches Saturnus Bio with Versant Ventures in $50M Build-to-Buy Deal Targeting Rare Genetic Cardiomyopathies
核心洞察
Merck (搜索) and Versant Ventures (搜索) have launched Saturnus Bio (搜索), a precision cardiology company focused on targeted gene modulation for rare monogenic cardiomyopathies.
The build-to-buy deal includes a $50 million upfront payment from Merck (搜索) to fund Saturnus' research, with exclusive rights to acquire the company later.
Genetic cardiomyopathies represent a market with no approved therapies addressing underlying genetic drivers, highlighting significant unmet medical need.
Merck (搜索), a leading global science and technology company, has entered a strategic research-stage collaboration with Saturnus Bio (搜索), a Versant Ventures (搜索)-founded biotech, to advance next-generation precision cardiology treatments for rare genetic cardiomyopathies. The build-to-buy deal, announced today, includes a $50 million upfront payment from Merck to fund Saturnus' research activities, securing a minority equity stake in the company along with exclusive rights to acquire Saturnus at a later stage.
The partnership targets rare monogenic cardiomyopathies—inherited heart muscle diseases caused by mutations in a single gene—for which there are currently no approved therapies that address the underlying genetic drivers.
A Precision Cardiology Platform
Saturnus Bio (搜索) is positioned as a next-generation precision cardiology company that utilizes targeted gene modulation to address rare monogenic cardiomyopathies with significant unmet need. The company aims to build a pipeline of first-in-class medicines for these conditions, though specific genes, disease subtypes, therapeutic modalities, and development timelines have not been disclosed.
"Through our partnership with Saturnus Bio (搜索), we aim to fast track the development of innovative therapies for genetic cardiomyopathies through precision cardiology, targeting the rare population impacted by these conditions," said David Weinreich, MD, Head of Research and Development and Chief Medical Officer, Healthcare business of Merck (搜索). "By leveraging Saturnus' expertise and cutting-edge approach, we can build upon our armed antibodies capabilities and explore novel directions to rapidly bring new, targeted treatments to patients."
Build-to-Buy Structure and Strategic Rationale
The deal structure includes the upfront $50 million payment, additional success-based preclinical milestones, and a pre-determined option payment should Merck (搜索) exercise its exclusive acquisition rights, along with success-based earnouts. This build-to-buy model allows pharmaceutical companies to help shape a young biotech from inception while deferring a full acquisition decision until early milestones are reached.
Versant Ventures (搜索) has a demonstrated track record with this company-creation model. Bayer acquired the remaining stake in BlueRock Therapeutics in 2019, three years after launching the cell therapy company with Versant and a $225 million investment, in a deal that valued BlueRock at approximately $1 billion. Roche exercised its option to acquire Inception 5, a company created with Versant focused on remyelination therapies for multiple sclerosis. More recently, AstraZeneca exercised its option to acquire SixPeaks Bio, a Swiss obesity biotech launched with Versant in 2024.
"The launch of Saturnus through a foundational partnership with Merck (搜索) exemplifies Versant's strategy of engaging with pharma to develop a new frontier of medicines in areas of important unmet medical need," said Rick Dewey, MD, an entrepreneur-in-residence at Versant Ventures (搜索) and CEO of Saturnus. "The company is in strong position to accelerate development of its pipeline of first-in-class medicines for genetic cardiomyopathies."
Addressing an Untapped Market
Genetic cardiomyopathies represent a vital entry point for Merck (搜索)'s cardiovascular business, addressing significant unmet need in a market characterized by no approved therapies for genetic drivers. The collaboration augments Merck's broader efforts to pursue precision medicine-defined indications and reinforces its strategy to enhance research productivity through indications that can be derisked via proper preclinical and early clinical testing.
Merck (搜索) is committed to leveraging advanced technologies and data science to accelerate the discovery and delivery of breakthrough medicines. The company, which generated sales of €21.1 billion across 65 countries in 2025, operates across life science, healthcare, and electronics, employing more than 62,000 people worldwide.
Saturnus Bio (搜索) remains at the research stage, and the companies have not yet disclosed the specific genetic targets, disease subtypes, or development timelines underpinning the platform.